Breaks Categories: News

ThursdayMar 24, 2022 2:11 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

Continue Reading

ThursdayMar 24, 2022 1:43 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board ("IRB") for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for the study. The company anticipates submitting its IND application in the second quarter, with hopes that the study will begin shortly thereafter. Calling the approval a “significant milestone,” the company noted that its mission is to provide safer, more effective solutions to address nicotine dependence…

Continue Reading

WednesdayMar 23, 2022 1:48 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtual Growth Conference. The event, presented by Maxim Group LLC and hosted by M-Vest, is slated to take place March 28-30, 2022. In addition to the company's corporate presentation available on demand for registered attendees, Climaco will participate in a live fireside chat moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group, at 2:30 p.m. ET on Wednesday,…

Continue Reading

ThursdayMar 17, 2022 11:09 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Makes Changes in Management

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO while the company searches for a full-time replacement. Edwards has garnered more than 35 years experience to her new position, including more than two decades of experience as a chief financial officer; she has served…

Continue Reading

TuesdayMar 15, 2022 10:51 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Medical Device Registration in New Zealand for Proprietary IoT System

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a medical device certification in New Zealand for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). This comes in coordination with Medical Kiwi Ltd. as local sponsor for the New Zealand certification. Medical Kiwi is a New Zealand-based leader in R&D, manufacturing, cultivation and distribution of medical cannabis and medical devices. “We are pleased to continue gaining traction with medical device registration around the world and are excited to…

Continue Reading

FridayMar 11, 2022 1:25 pm

BioMedNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba

AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The…

Continue Reading

WednesdayMar 09, 2022 12:40 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both…

Continue Reading

TuesdayMar 08, 2022 1:28 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will host a fireside chat with Scoth Henry, managing director and head of pharmaceuticals research at Roth Capital Partners, on Tuesday, March 15. In addition to the live fireside chat, InMed’s virtual Roth Conference presentation is now available on-demand by visiting https://ibn.fm/fsWdF. A webcast will be made available to investors following the event in the investor relations section of…

Continue Reading

TuesdayMar 08, 2022 12:23 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Approval from Health Canada Recognizing RYAH Smart Medical Inhaler System as Medical Device

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a Health Canada Medical Device License (“MDL”) for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). According to the update, Health Canada License number 107475 allows RYAH to market its Smart Medical Inhaler System to medical patients in Canada and potentially represents a significant boost to RYAH’s growth strategy. “The approval from Health Canada recognizing the RYAH Smart Inhaler System as a medical device is a major step towards…

Continue Reading

ThursdayMar 03, 2022 12:37 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Operationally 2021 was a terrific year for the company as we established the global framework for building and expanding our potentially pivotal clinical study of Berubicin for the treatment of GBM. Our priority remains focused…

Continue Reading